Granot-Hershkovitz, Einat
Spitzer, Brian
Yang, Yunju
Tarraf, Wassim
Yu, Bing http://orcid.org/0000-0003-4818-1077
Boerwinkle, Eric
Fornage, Myriam http://orcid.org/0000-0003-0677-8158
Mosley, Thomas H.
DeCarli, Charles http://orcid.org/0000-0003-1914-2693
Kristal, Bruce S.
González, Hector M.
Sofer, Tamar http://orcid.org/0000-0001-8520-8860
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R21AG070644)
Article History
Received: 9 September 2022
Revised: 14 April 2023
Accepted: 19 April 2023
First Online: 29 April 2023
Competing interests
: BSK is the inventor of general metabolomics-related IP that has been licensed to Metabolon via Weill Medical College of Cornell University and for which he receives royalty payments via Weill Medical College of Cornell University. He also consults for and has a small equity interest in the company. Metabolon offers biochemical profiling services and is developing molecular diagnostic assays detecting and monitoring disease. Metabolon has no rights or proprietary access to the research results presented and/or new IP generated under these grants/studies. BSK’s interests were reviewed by the Brigham and Women’s Hospital and Partners Healthcare in accordance with their institutional policy. Accordingly, upon review, the institution determined that BSK’s financial interest in Metabolon does not create a significant financial conflict of interest (FCOI) with this research. The addition of this statement, where appropriate, was explicitly requested and approved by BWH.